Translate
About
Psyence Biomedical Ltd. Common Shares (NASDAQ:PBM) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Apr 20 2026
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Apr 17 2026
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Apr 14 2026
Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement
Apr 8 2026
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Financials
Revenue
$0
Market Cap
$5.8 M
EPS
-389.98